VEGFA and inflammation: However, anti-VEGF therapy carries risks, including reactivation requiring repeat injections, the need for frequent follow-ups, and increased risks of conjunctival and retinal hemorrhage, elevated intraocular pressure, retinal and choroidal ischemia, worsening retinal traction, cataracts, intraocular inflammation, retinal detachment, and potential systemic effects.